Correction: Intra-tumoral sphingobacterium multivorum promotes triple-negative breast cancer progression by suppressing tumor immunosurveillance

Abstract

Correction: Mol Cancer 24, 6 (2025)

https://doi.org/10.1186/s12943-024-02202-9

Following the publication of the original article [1], the authors would like to update the texts under the Fig. 4 caption or legend.

The texts under the Fig. 4 caption currently reads:

Propionylcarnitine which was decreased by S. multivorum inhibits tumor growth in vivo. (A) Heatmap showing potential biomarker levels in mouse tumors. The screening criteria were p < 0.05 and |log2FC| ≥ 0 for unidimensional analysis, and VIP value > 1 for multidimensional analysis. (B) Pathway enrichment analysis of differential metabolites using pathway-associated metabolite sets (SMPDB). (C) Volcano plot showing the differential metabolites based on one-dimensional statistical screening. Differential metabolites were considered significant at a threshold of p < 0.05 and |log2FC| ≥ 0. (D-F) Concentration of short-chain acylcarnitine metabolites in mouse tumors. (G) The effect of propionylcarnitine on cell viability of MDA-MB-231, BT20, and 4T1 cell lines in vitro. (H) The effect of propionylcarnitine on spleen lymphocyte viability in BALB/c mice. (I) The number of Treg cells in splenic lymphocytes of BALB/c mice by flow cytometry analysis. (L) Images of representative 4T1 subcutaneous tumors after the intra-tumoral injection of the S. multivorum in BALB/c mice. PBS served as a negative control. 2 × 10⁷ CFU of S. multivorum were injected into subcutaneous tumors as described above. 150 mg/kg propionylcarnitine was injected into the tumor twice a week. After 26 days, the subcutaneous tumors were isolated and shown. (M) Tumor growth curve in BALB/c mice. (N) Tumor weight in BALB/c mice. (O) Body weight of BALB/c mice. Statistical significance was determined by an unpaired two-tailed Student’s t-test for (D-F) and ANOVA statistical test with a Tukey’s post-hoc analysis for (H-K, N). Significance levels are denoted as *p < 0.05; **p < 0.01; ***p < 0.001.

The texts under the Fig. 4 caption should read:

Propionylcarnitine which was decreased by S. multivorum inhibits tumor growth in vivo. (A) Heatmap showing potential biomarker levels in mouse tumors. The screening criteria were p < 0.05 and |log2FC| ≥ 0 for unidimensional analysis, and VIP value > 1 for multidimensional analysis. (B) Pathway enrichment analysis of differential metabolites using pathway-associated metabolite sets (SMPDB). (C) Volcano plot showing the differential metabolites based on one-dimensional statistical screening. Differential metabolites were considered significant at a threshold of p < 0.05 and |log2FC| ≥ 0. (D-F) Concentration of short-chain acylcarnitine metabolites in mouse tumors. (G) The effect of pionylcarnitine, hexanylcarnitine, and butyrylcarnitine on cell viability of 4T1 cell lines in vitro. (H) The effect of propionylcarnitine on spleen lymphocyte viability in BALB/c mice. (I-K) The number of Treg cells in splenic lymphocytes of BALB/c mice treated with propionylcarnitine, hexanylcarnitine and butyrylcarnitine respectively by flow cytometry analysis. (L) Images of representative 4T1 subcutaneous tumors after the intra-tumoral injection of the S. multivorumin BALB/c mice. PBS served as a negative control. 2 × 107 CFU of S. multivorum were injected into subcutaneous tumors as described above. 150 mg/kg propionylcarnitine was injected into the tumor twice a week. After 26 days, the subcutaneous tumors were isolated and shown. (M) Tumor growth curve in BALB/c mice. (N) Tumor weight in BALB/c mice. (O) Body weight of BALB/c mice. Statistical significance was determined by an unpaired two-tailed Student’s t-test for (D-F) and ANOVA statistical test with a Tukey’s post-hoc analysis for (H-K, N). Significance levels are denoted as *p < 0.05; **p < 0.01; ***p < 0.001.

1. Mai Z, Fu L, Su J, et al. Intra-tumoral sphingobacterium multivorum promotes triple-negative breast cancer progression by suppressing tumor immunosurveillance. Mol Cancer. 2025;24:6. https://doi.org/10.1186/s12943-024-02202-9.

   Article CAS PubMed PubMed Central Google Scholar

Download references

Author notes

1. Zhikai Mai and Jiyan Su contributed equally to this work.

Authors and Affiliations

1. Foshan Maternity and Child Healthcare Hospital; School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 515150, China

   Zhikai Mai, Jiyan Su & Chenglai Xia

2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

   Liwu Fu

3. School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, 999077, China

   Kenneth K.W. To

4. Department of Breast, Thyroid and Head-Neck Surgery, Yuebei People’s Hospital of Shantou University, Shaoguan, China

   Chuansheng Yang

Authors

1. Zhikai MaiView author publications

   You can also search for this author in PubMed Google Scholar

2. Liwu FuView author publications

   You can also search for this author in PubMed Google Scholar

3. Jiyan SuView author publications

   You can also search for this author in PubMed Google Scholar

4. Kenneth K.W. ToView author publications

   You can also search for this author in PubMed Google Scholar

5. Chuansheng YangView author publications

   You can also search for this author in PubMed Google Scholar

6. Chenglai XiaView author publications

   You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Liwu Fu or Chenglai Xia.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s12943-024-02202-9.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Mai, Z., Fu, L., Su, J. et al. Correction: Intra-tumoral sphingobacterium multivorum promotes triple-negative breast cancer progression by suppressing tumor immunosurveillance. Mol Cancer 24, 33 (2025). https://doi.org/10.1186/s12943-025-02237-6

Download citation

• Published: 27 January 2025

• DOI: https://doi.org/10.1186/s12943-025-02237-6

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative